Page 3 - Department Of Urologic Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Department of urologic sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Department Of Urologic Sciences Today - Breaking & Trending Today

PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer

Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results. ....

United Kingdom , British Columbia , Fred Saab , Kimn Chi , University Of British Columbia , Department Of Urologic Sciences , Vancouver Prostate Center , University Of Montreal Hospital Center , Department Of Medicine , Genitourinary Cancers Symposium , Montreal Hospital Center , Urologic Sciences , Cancers Symposium , Presented February , Metastatic And Advanced Prostate Cancer , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Ovarian Cancer , Alignant Ovarian Neoplasm , Parp Inhibitors , Parp Inhibition ,

AI helps researchers screen antiviral drugs to treat COVID-19

With AI, Dr. Artem Cherkasov and researchers took 19 days not 10 years to review 40 billion compounds to find potential COVID-19 drugs ....

British Columbia , Kevin Griffin , Paul Rennie , Artem Cherkasov , Vancouver Coastal Health Research Institute , Vancouver Prostate Centre , Royal Society Of Chemistry , Roche Pharmaceuticals , Department Of Urologic Sciences , Steve Bosch , Brandy Shore , Urologic Sciences , Chemical Science , Royal Society , Deep Docking , Democratizing Drug Discovery ,

Human studies begin on artificial Intelligence discovered COVID-19 treatment with up to 97 percent effectiveness

Press release content from PR Newswire. The AP news staff was not involved in its creation. ....

United States , United Kingdom , Baton Rouge , Chris Galliano , Scott Henderson , Samuelj Bentley , Supratik Mukhopadhyay , University Scholar Adjunct Professor , Department Of Computer Science , University Of British Columbia , Research Institute , Louisiana State University , Department Of Urologic Sciences , Global Diseases Initiative , Urologic Sciences , British Columbia , Neglected Global Diseases Initiative , Skymount Medical , Coronavirus Pandemic , Pr Newswire , Artificial Intelligence , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , தடியடி ரூஜ் , ஸ்காட் ஹென்டர்சன் , துறை ஆஃப் கணினி அறிவியல் ,

iCo Therapeutics Subsidiary to present Oral Amphotericin B / | The Kingston Whig Standard

Article content
Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Amphotericin B Technologies, Inc (“Amp B Tech” or the “Company”), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) (“iCo”), announced today that two presentations related to research on the effectiveness of the Company’s Oral Amphotericin B formulation (“iCo 019”) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium –
Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharmaceutical Sciences. (https://www.cspscanada.org/symposium-events/2021-csps-symposium/)
We apologize, but this video has failed to load. ....

United States , United Kingdom , British Columbia , William Jarosz , Peter Hnik , Research Results At National Pharmaceutical Sciences Meeting , Co Therapeutics Subsidiary , Canadian Society For Pharmaceutical Sciences , Amphotericinb Technologies Inc Ampb Tech , University Of Saskatchewan , Company Oral Amphotericin , Regulatory Services Provider , Newsfile Corp , Ico Therapeutics Inc , Department Of Urologic Sciences , Vico Therapeutics , Venture Exchange , National Pharmaceutical Sciences Meeting , Amphotericinb Technologies , Pharmaceutical Sciences , Canadian Society , Chief Executive Officer , Ampb Tech , Chief Scientific Officer , Neglected Global Diseases Initiative , Adjunct Professor ,

iCo Therapeutics Inc.: iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting

(2)
Vancouver, British Columbia (Newsfile Corp. - May 11, 2021) - Amphotericin B Technologies, Inc ( Amp B Tech or the Company ), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) ( iCo ), announced today that two presentations related to research on the effectiveness of the Company s Oral Amphotericin B formulation ( iCo 019 ) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium -
Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharmaceutical Sciences. (https://www.cspscanada.org/symposium-events/2021-csps-symposium/)
William Jarosz, Chief Executive Officer of iCo and Amp B Tech, noted, ....

United States , United Kingdom , British Columbia , William Jarosz , Peter Hnik , Canadian Society For Pharmaceutical Sciences , British Columbia Newsfile Corp , Amphotericinb Technologies Inc Ampb Tech , University Of Saskatchewan , Company Oral Amphotericin , Regulatory Services Provider , Ico Therapeutics Inc , Department Of Urologic Sciences , Vico Therapeutics , Venture Exchange , Canadian Society , Chief Executive Officer , Ampb Tech , Chief Scientific Officer , Neglected Global Diseases Initiative , Adjunct Professor , Urologic Sciences , Chief Medical Officer , Assistant Professor Ellen Wasan , Pharmaceutical Sciences , Blind Randomized Clinical Study ,